Literature DB >> 21883346

Histological and molecular features of lipomatous and nonlipomatous adipose tissue in familial partial lipodystrophy caused by LMNA mutations.

D Araújo-Vilar1, B Victoria, B González-Méndez, F Barreiro, B Fernández-Rodríguez, R Cereijo, J M Gallego-Escuredo, F Villarroya, A Pañeda-Menéndez.   

Abstract

OBJECTIVES: Type 2 familial partial lipodystrophy (FPLD2) is a rare adipose tissue (AT) disease caused by mutations in LMNA, in which lipomas appear occasionally. In this study, we aimed to histologically characterize FPLD2-associated lipomatosis and study the expression of genes and proteins involved in cell cycle control, mitochondrial function, inflammation and adipogenesis. DESIGN AND PATIENTS: One lipoma and perilipoma fat from each of four subjects with FPLD2 and 10 control subjects were analysed by optical microscopy. The presence of inflammatory cells was evaluated by immunohistochemistry. Real-time RT-PCR and Western blot were used to evaluate gene and protein levels.
RESULTS: Adipocytes from lipodystrophic patients were significantly larger than those of controls, in both the lipomas and perilipoma fat. Lipodystrophic AT exhibited CD68(+) macrophages and CD3(+) lymphocytes infiltration. TP53 expression was reduced in all types of lipomas. At protein level, C/EBPβ, p53 and pRb were severely disturbed in both lipodystrophic lipomas and perilipoma fat coming from lipoatrophic areas, whereas the expression of CEBPα was normal. Mitochondrial function genes were less expressed in lipoatrophic fat. In both lipomas and perilipoma fat from lipoatrophic areas, the expression of adipogenes was lower than controls.
CONCLUSIONS: Even in lipomas, the adipogenic machinery is impaired in lipodystrophic fat coming from lipoatrophic regions in FPLD2, although the histological phenotype is near-normal, exhibiting low-grade inflammatory features. Our results suggest that the p53 pathway and some adipogenic proteins, such as CEBPα, could contribute to the maintenance of this near normal phenotype in the remnant AT present in these patients.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21883346     DOI: 10.1111/j.1365-2265.2011.04208.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Extracellular matrix remodeling and transforming growth factor-β signaling abnormalities induced by lamin A/C variants that cause lipodystrophy.

Authors:  Caroline Le Dour; Wei Wu; Véronique Béréziat; Jacqueline Capeau; Corinne Vigouroux; Howard J Worman
Journal:  J Lipid Res       Date:  2016-11-14       Impact factor: 5.922

2.  LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A.

Authors:  Yiping Tu; Sofía Sánchez-Iglesias; David Araújo-Vilar; Loren G Fong; Stephen G Young
Journal:  Nucleus       Date:  2016-09-02       Impact factor: 4.197

3.  Cbl Proto-Oncogene B (CBLB) c.197A>T Mutation Induces Mild Metabolic Dysfunction in Partial Type I Multiple Symmetric Lipomatosis (MSL).

Authors:  Ke Chen; Xinxing Wan; Liling Zhao; Shaoli Zhao; Lin Peng; Wenjun Yang; Jingjing Yuan; Liyong Zhu; Zhaohui Mo
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-06       Impact factor: 3.168

Review 4.  What lipodystrophies teach us about the metabolic syndrome.

Authors:  Jake P Mann; David B Savage
Journal:  J Clin Invest       Date:  2019-08-05       Impact factor: 14.808

5.  LMNA Sequences of 60,706 Unrelated Individuals Reveal 132 Novel Missense Variants in A-Type Lamins and Suggest a Link between Variant p.G602S and Type 2 Diabetes.

Authors:  Alyssa Florwick; Tejas Dharmaraj; Julie Jurgens; David Valle; Katherine L Wilson
Journal:  Front Genet       Date:  2017-06-15       Impact factor: 4.599

Review 6.  Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives.

Authors:  Corinne Vigouroux; Anne-Claire Guénantin; Camille Vatier; Emilie Capel; Caroline Le Dour; Pauline Afonso; Guillaume Bidault; Véronique Béréziat; Olivier Lascols; Jacqueline Capeau; Nolwenn Briand; Isabelle Jéru
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

Review 7.  Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People

Authors:  Samim Özen; Barış Akıncı; Elif A. Oral
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-08-22

8.  Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2.

Authors:  Callie A S Corsa; Carolyn M Walsh; Devika P Bagchi; Maria C Foss Freitas; Ziru Li; Julie Hardij; Katrina Granger; Hiroyuki Mori; Rebecca L Schill; Kenneth T Lewis; Jessica N Maung; Ruth D Azaria; Amy E Rothberg; Elif A Oral; Ormond A MacDougald
Journal:  Diabetes       Date:  2021-06-04       Impact factor: 9.337

9.  The Molecular Signature of HIV-1-Associated Lipomatosis Reveals Differential Involvement of Brown and Beige/Brite Adipocyte Cell Lineages.

Authors:  Rubén Cereijo; José Miguel Gallego-Escuredo; Ricardo Moure; Joan Villarroya; Joan Carles Domingo; Joan Fontdevila; Esteban Martínez; Maria del Mar Gutiérrez; María Gracia Mateo; Marta Giralt; Pere Domingo; Francesc Villarroya
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

Review 10.  Lipodystrophic laminopathies: Diagnostic clues.

Authors:  Cristina Guillín-Amarelle; Antía Fernández-Pombo; Sofía Sánchez-Iglesias; David Araújo-Vilar
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.